{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"This is measurement is summarized via bone marrow biopsy results and blood assays through 3 years.\n\nAnti-tumor response is assessed according to Center for International Blood and Marrow Transplant Research (CIBMTR.org) criteria.\n\nFor multiple myeloma, based on assessment of serum and urine immunofixation, the presence or absence of soft tissue plasmacytomas and analyses of bone marrow aspirate and biopsy samples, response categories include stringent complete remission (sCR), complete remission (CR), near CR (nCR) very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD).\n\nFor AL amyloidosis, based on assessment of serum and urine immunofixation and serum free light chain ratio, hematologic response categories include complete response, very good partial response, partial response, no response/stable disease and progressive disease. Organ responses are also assessed according to organ specific criteria.","groups":[{"description":"Single arm combined bone marrow and kidney transplantation\n\nTacrolimus: Tacrolimus starting on Day -1\n\nEquine Anti-thymocyte globulin: 20 mg/kg IV on Days -3, -1, +1, +3\n\nKidney transplant from a related donor: On Day 0 the renal transplant is performed according to standard surgical techniques.\n\nBone marrow transplant from a related donor: Donor bone marrow (\\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.\n\nTotal body irradiation 400 centigray (200 cGy X 2): On transplant day -1","id":"OG000","title":"Bone Marrow and Kidney RECIPIENTS"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One bone marrow/kidney recipient was enrolled and treated on this trial.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Anti-Tumor Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}